Sophiris Bio Inc. is a biopharmaceutical company that is focused on late-stage clinical developments for urological diseases. The company is dedicated to the development of topsalysin, which is currently in Phase 2 clinical trials for the treatment of localized prostate cancer and Phase 3 clinical trials for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Topsalysin is a highly potent ablative agent, which is selective and targeted, and only activated by enzymatically active PSA found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells.